A Word to the Wise About Intranasal Esketamine
2019; American Psychiatric Association; Volume: 176; Issue: 6 Linguagem: Inglês
10.1176/appi.ajp.2019.19040423
ISSN1535-7228
Autores Tópico(s)Anesthesia and Sedative Agents
ResumoBack to table of contents Previous article Next article CommentaryFull AccessA Word to the Wise About Intranasal EsketamineAlan F. Schatzberg, M.D.Alan F. Schatzberg, M.D.Published Online:21 May 2019https://doi.org/10.1176/appi.ajp.2019.19040423AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail Rarely has there been so much anticipation for a new antidepressant as has been seen for intranasal esketamine, the putatively more effective enantiomer of ketamine. This reflects the exposure given to studies on the off-label intravenous use of racemic mixture ketamine for refractory depression and its ensuing availability via ketamine clinics and infusion centers. Intranasal esketamine represents a novel way of administering the agent and is the subject of the report in this issue by Popova et al. (1).This pivotal phase 3 study demonstrated rapid separation (by 24–48 hours) for esketamine plus antidepressant compared with placebo plus antidepressant, with continued separation with repeated administration up to 28 days. Esketamine was administered twice weekly for 4 weeks. This trial was presented as part of the recent approval of esketamine by the U.S. Food and Drug Administration (FDA) for refractory depression. During that process, a number of worrisome findings were revealed that should give potential users some pause and call for a concise framework for assessing the risk-benefit balance for using this formulation of ketamine.The phase 3 program included three pivotal trials, and in only the Popova et al. study was there a statistically significant separation from placebo on the primary endpoint. In the other two trials, mean differences in change scores were similar to those in this report but did not attain statistical significance. The effect size in the Popova et al. study was 0.30, that is, in the mild range. With the use of saline as a control for esketamine, the reader should have cause to wonder, with a small effect and a rather limited control comparison, whether efficacy has been truly demonstrated. The control condition produced little in the way of side effects similar to those of esketamine, although some individuals seemed to experience dissociation with placebo. Moreover, as demonstrated in Figure 1 in the article, the difference was seen early and was maintained throughout the trial, but there was no further gain in advantage beyond the initial separation.The study design in this development program called for an antidepressant to be started at the same time as esketamine or placebo. Since the patients were treated with the combination of an active antidepressant plus either esketamine or placebo, the data make one wonder whether one really needs to continue esketamine beyond initial use. Why not use it only once or twice for 1 or 2 weeks rather than twice weekly for 4 weeks? This question needs to be considered in the context of what ketamine is—an anesthetic agent that has been abused in this country and elsewhere in various formulations. A recent report on a rodent study points out that continued use of ketamine maintains and extends its acute neuronal spine–producing effects to produce stronger interneuron communication, suggesting that some continued use is necessary to maintain biological effects (2). But how much and for how long in humans? The package insert for the drug in refractory depression currently recommends twice-weekly administration for 4 weeks, once weekly for 4 weeks, and then, beyond 8 weeks, once weekly or once every 2 weeks, aiming for the least frequent dosing to maintain response or remission.Our group has reported in this journal (3) that the acute antidepressant effects of ketamine are blocked when the patient is pretreated with oral naltrexone, indicating that ketamine’s antidepressant effects are mediated by mu opioid agonism. We could not determine whether the effect was a release of endogenous opioids or some binding to the mu opioid receptor. Also, our results did not rule out that NMDA antagonism may be needed for maintaining the response (3). The opioid properties may explain the drug’s abusability and raise concerns regarding liability with longer-term use.The drug’s opioid properties need to be considered when considering how best to use it. A release of endogenous opioids by ketamine has been reported by Pacheco et al. (4) in a rodent pain study where antinociception was blocked by the mu opioid receptor antagonist naloxone, and this mechanism may be unique for ketamine. At first glance, that release would suggest a risk of developing tachyphylaxis and risk of withdrawal symptoms. But ketamine has been reported to reduce the risk of tolerance with opioids (5) and, at anesthetic doses, to reduce postsurgery opioid use, likely through its NMDA antagonism effects (6). Thus, this unique pharmacology may not be a problem with “continued intermittent” use. Indeed, it was recently reported that endogenous and synthetic opioids behave differently at the Golgi membrane levels (7), and that may explain differences in risk. At any rate, further studies, both in animals and humans, are needed to understand the opioid effects of ketamine.Reasons for concern, however, rest with the known abusability of ketamine in humans, and these issues were raised in an earlier commentary on ketamine in this journal (8). They are reinforced by the data in the FDA’s Briefing Document (9), in which the manufacturer reported on a drug relapse prevention/discontinuation study where patients were treated with ketamine plus antidepressant for 16 weeks and then tapered to once per week to once per 2 weeks before being randomized to continuing treatment with antidepressant plus ketamine or antidepressant plus placebo. The study was used as a second positive trial to support proof of efficacy, which, as previously noted (8), is a somewhat unusual application in proof of efficacy. Patients assigned to placebo showed significantly greater relapse rates by 2 weeks, which is a much shorter time frame than other discontinuation studies with known antidepressants where patients are actually taken off all drugs and differences in relapse are observed by 1 month or more (8). Relapse rates on discontinuing esketamine reached 40% by 3–4 months even though patients were receiving known antidepressants. This raises the question as to whether patients should be receiving esketamine for even longer periods—or would that be even more risky? What is more worrisome than this rapid relapse coming off even less frequent esketamine administration were the three suicides that occurred 4–20 days after the last dose of esketamine (there were none in the placebo group). Two of the patients who died by suicide showed no previous signs of suicidal activity during the study, either at baseline or at the last visit. This suggests a protracted withdrawal reaction, as has been reported with opioids, and one that is different from the more physical withdrawal symptoms seen acutely with opioids (10).Given the rapid relapse and potential suicide risk, it is hard to know what to recommend to clinicians. Should they really continue to use the agent beyond an acute course? For how long? In whom? Unfortunately, the long-term discontinuation study that demonstrates efficacy may not be the best paradigm for a drug of abuse where coming off the drug may be more important and informative than the period when taking it. The FDA Briefing Document (9, p. 42) states, in regard to the suicides, that “given the small number of cases, the severity of the patients’ underlying illness, and the lack of a consistent pattern among these cases, it is difficult to consider these deaths as drug-related.” This appears misguided. Discontinuation reactions can certainly be due to the drug even though patients are not taking them at that time. Unfortunately, when one approaches ketamine as another antidepressant rather than a drug of abuse, this type of trap is easy to fall into, and in the end, such mistakes can be catastrophic. We have witnessed four decades of supposedly new and safer opioids that have turned out often to be, if anything, even more abusable and lethal. The FDA has asked the company to track patients for 3 years, and these data should help. In addition, the restricted distribution limits patients’ access to the drug to approved medical settings, with patients observed for side effects for 2 hours.So, where are we? Intranasal esketamine represents an easier method of administration than intravenous administration of ketamine. Do we have clear evidence of efficacy? Maybe? How strong is the efficacy? Apparently mild. Do we have a real sense of how long and how often to prescribe it? It’s not entirely clear. If patients lose response, should we increase the frequency of administration? This could be problematic. Can coming off the drug be problematic? Data suggest that it could be an issue. Taken together, there are more questions than answers with intranasal esketamine, and care should be exercised in its application in clinical practice. Only time will tell how useful it will be. Still, the agent could be helpful to many patients with refractory depression, and efforts to develop rapidly acting agents for severely depressed patients need to be applauded.Stanford University School of Medicine, Stanford, Calif.Send correspondence to Dr. Schatzberg ([email protected]).Dr. Schatzberg has received grant support from Janssen; he has served as a consultant for Alkermes, Avanir, Brain Resource, Bracket, Compass, Delpor, Epiodyne, GLG, Jazz, Janssen Pharmaceuticals, Lundbeck/Takeda, McKinsey and Company, Merck, Myriad Genetics, Neuronetics, Owl Analytics, Pfizer, Sage, Sunovion, and Xhale; he holds equity in Corcept (co-founder), Delpor, Dermira, Epiodyne, Gilead, Incyte Genetics, Intersect ENT, Madrigal, Merck, Owl Analytics, Seattle Genetics, Titan, and Xhale; and he is listed as an inventor on patents for pharmacogenetics and antiglucocorticoid use in the prediction of antidepressant response.References1 Popova V, Daly EJ, Trivedi M, et al.: Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study. Am J Psychiatry 2019; 176:428–438Link, Google Scholar2 Moda-Sava RN, Murdock MH, Parekh PK, et al.: Sustained rescue of prefrontal circuit dysfunction by antidepressant-induced spine formation. Science 2019; 364:eaat8078Medline, Google Scholar3 Williams NR, Heifets BD, Blasey C, et al.: Attenuation of antidepressant effects of ketamine by opioid receptor antagonism. Am J Psychiatry 2018; 175:1205–1215Link, Google Scholar4 Pacheco Dda F, Romero TR, Duarte ID: Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors. Brain Res 2014; 1562:69–75Crossref, Medline, Google Scholar5 Trujillo KA, Akil H: Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991; 251:85–87Crossref, Medline, Google Scholar6 Jonkman K, Dahan A, van de Donk T, et al.: Ketamine for pain. F1000 Res 2017; 6(F1000 Faculty Rev):1711 (https://doi.org/10.12688/f1000research.11372.1)Crossref, Google Scholar7 Stoeber M, Jullié D, Lobingier BT, et al.: A genetically encoded biosensor reveals location bias of opioid drug action. Neuron 2018; 98:963–976.e5Crossref, Medline, Google Scholar8 Schatzberg AF: A word to the wise about ketamine. Am J Psychiatry 2014; 171:262–264Link, Google Scholar9 US Food and Drug Administration: Briefing information for the Feb 12, 2019 joint meeting of the Psychopharmacologic Drugs Advisory Committee (PDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM). https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM630970.pdfGoogle Scholar10 Satel SL, Kosten TR, Schuckit MA, et al.: Should protracted withdrawal from drugs be included in DSM-IV? Am J Psychiatry 1993; 150:695–704Link, Google Scholar FiguresReferencesCited byDetailsCited byRole of group II metabotropic glutamate receptors in ketamine's antidepressant actionsPharmacology Biochemistry and Behavior, Vol. 223Oral ketamine for depression: An updated systematic review31 January 2023 | The World Journal of Biological Psychiatry, Vol. 376When Still Water Runs Deep: The Complexities of Clinically Repurposing FDA Approved TherapiesClinical Therapeutics, Vol. 44, No. 11A Pilot Study of Ketamine Infusion after Suicide Attempt: New Frontiers in Treating Acute Suicidality in a Real-World Medical Setting24 October 2022 | International Journal of Environmental Research and Public Health, Vol. 19, No. 21New antidepressants: New day or false dawn?European Neuropsychopharmacology, Vol. 63Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search29 June 2022 | Molecular Psychiatry, Vol. 27, No. 10Suicidal behavior-advances in clinical and neurobiological research and improvement of prevention strategiesWorld Journal of Psychiatry, Vol. 12, No. 9Emergence of Ketamine as a Rapid Acting Antidepressant: Mechanistic Insights and Future Directions14 September 2022Mapping consent practices for outpatient psychiatric use of ketamineJournal of Affective Disorders, Vol. 312Long-term safety of ketamine and esketamine in treatment of depression19 April 2022 | Expert Opinion on Drug Safety, Vol. 21, No. 6Effects of intranasal (S)-ketamine on Veterans with co-morbid treatment-resistant depression and PTSD: A retrospective case serieseClinicalMedicine, Vol. 48Safety concerns on the abuse potential of esketamine: Multidimensional analysis of a new anti‐depressive drug on the market23 December 2021 | Fundamental & Clinical Pharmacology, Vol. 36, No. 3The antidepressant effect and safety of non-intranasal esketamine: A systematic review12 May 2022 | Journal of Psychopharmacology, Vol. 36, No. 5Suicide versus Accidental Death by Autoerotic Asphyxiation in a Patient Receiving Intravenous Ketamine for DepressionCase Reports in Psychiatry, Vol. 2022Neurological Adverse Events Associated With Esketamine: A Disproportionality Analysis for Signal Detection Leveraging the FDA Adverse Event Reporting System8 April 2022 | Frontiers in Pharmacology, Vol. 13Time will tell. Reply to “Comments to pharmacological and behavioral divergence of ketamine enantiomers by Jordi Bonaventura et al.” by Chen et al.22 February 2022 | Molecular Psychiatry, Vol. 27, No. 4Research advances in the clinical application of esketamine5 March 2022 | Ibrain, Vol. 8, No. 1Non-parenteral Ketamine for Depression: A Practical Discussion on Addiction Potential and Recommendations for Judicious Prescribing14 February 2022 | CNS Drugs, Vol. 36, No. 3Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study6 December 2021 | BJPsych Open, Vol. 8, No. 1Ketamine treatment for depression: A model of care13 August 2021 | Australian & New Zealand Journal of Psychiatry, Vol. 55, No. 12Pharmacological and behavioral divergence of ketamine enantiomers: implications for abuse liability15 April 2021 | Molecular Psychiatry, Vol. 26, No. 11Ketamine for Bipolar Depression: A Systematic Review30 April 2021 | International Journal of Neuropsychopharmacology, Vol. 24, No. 7A Potential Case of Acute Ketamine Withdrawal: Clinical Implications for the Treatment of Refractory DepressionNichole Roxas, M.D., M.P.H., Chaarushi Ahuja, B.S., Jessica Isom, M.D., M.P.H., Samuel T. Wilkinson, M.D., Noah Capurso, M.D., M.H.S.16 July 2021 | American Journal of Psychiatry, Vol. 178, No. 7Online news media reporting of ketamine as a treatment for depression from 2000 to 20171 July 2021 | Irish Journal of Psychological MedicineSynthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and ImplementationRoger S. McIntyre, M.D., Joshua D. Rosenblat, M.D., M.Sc., Charles B. Nemeroff, M.D., Ph.D., Gerard Sanacora, M.D., Ph.D., James W. Murrough, M.D., Ph.D., Michael Berk, Ph.D., M.B.B.Ch., Elisa Brietzke, M.D., Ph.D., Seetal Dodd, Ph.D., Philip Gorwood, M.D., Ph.D., Roger Ho, M.D., M.B.B.S., Dan V. Iosifescu, M.D., Carlos Lopez Jaramillo, M.D., Ph.D., Siegfried Kasper, M.D., Kevin Kratiuk, B.Pharm., Jung Goo Lee, M.D., Ph.D., Yena Lee, H.B.Sc., Leanna M.W. Lui, Rodrigo B. Mansur, M.D., Ph.D., George I. Papakostas, M.D., Mehala Subramaniapillai, M.Sc., Michael Thase, M.D., Eduard Vieta, M.D., Ph.D., Allan H. Young, M.Phil., M.B.Ch.B., Carlos A. ZarateJr., M.D., Stephen Stahl, M.D., Ph.D.17 March 2021 | American Journal of Psychiatry, Vol. 178, No. 5The Future of Ketamine in the Treatment of Teen DepressionTapan Parikh, M.D., M.P.H., John T. Walkup, M.D.1 April 2021 | American Journal of Psychiatry, Vol. 178, No. 4Corticotropin Releasing Hormone Signaling in the Bed Nuclei of the Stria Terminalis as a Link to Maladaptive Behaviors19 March 2021 | Frontiers in Neuroscience, Vol. 15Recent developments in geriatric psychopharmacology5 February 2021 | Expert Review of Clinical Pharmacology, Vol. 14, No. 3Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms20 February 2021 | Pharmacological Reports, Vol. 28The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L’humeur Et De L’anxiété (Canmat) Concernant L’utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur11 November 2020 | The Canadian Journal of Psychiatry, Vol. 66, No. 2Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System27 August 2020 | Psychotherapy and Psychosomatics, Vol. 90, No. 1Cognitive Behavioral Therapy to Sustain the Antidepressant Effects of Ketamine in Treatment-Resistant Depression: A Randomized Clinical Trial29 June 2021 | Psychotherapy and Psychosomatics, Vol. 90, No. 5IMPORTANCE trial: a provisional study-design of a single-center, phase II, double-blinded, placebo-controlled, randomized, 4-week study to compare the efficacy and safety of intranasal esketamine in chronic opioid refractory pain22 January 2021 | F1000Research, Vol. 10“Novel Psychopharmacology for Depressive Disorders”9 April 2021Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysisJournal of Affective Disorders, Vol. 278Long-term treatment of depression with intranasal esketamine: Is it justified?Asian Journal of Psychiatry, Vol. 54Mechanisms associated with the antidepressant-like effects of L-655,70820 July 2020 | Neuropsychopharmacology, Vol. 45, No. 13Bipolar depression: a major unsolved challenge6 January 2020 | International Journal of Bipolar Disorders, Vol. 8, No. 1Agmatine potentiates antidepressant and synaptic actions of ketamine: Effects on dendritic arbors and spines architecture and Akt/S6 kinase signalingExperimental Neurology, Vol. 333Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence15 June 2020 | Expert Opinion on Drug Safety, Vol. 19, No. 8Predicting and Managing Treatment Non-response in Posttraumatic Stress Disorder23 March 2020 | Current Treatment Options in Psychiatry, Vol. 7, No. 2Are we repeating mistakes of the past? A review of the evidence for esketamine27 May 2020 | The British Journal of Psychiatry, Vol. 2Ketamine and nitrous oxide: The evolution of NMDA receptor antagonists as antidepressant agentsJournal of the Neurological Sciences, Vol. 412Ketamine: Leading us into the future for development of antidepressantsBehavioural Brain Research, Vol. 383Overlap in the neural circuitry and molecular mechanisms underlying ketamine abuse and its use as an antidepressantBehavioural Brain Research, Vol. 384Conformational flexibility within the small domain of human serine racemase3 February 2020 | Acta Crystallographica Section F Structural Biology Communications, Vol. 76, No. 2Ketamine and esketamine for suicidal ideation: Recent progress and practical issues12 December 2019 | Australian & New Zealand Journal of Psychiatry, Vol. 54, No. 2Ketamine, Esketamine, and A New Generation of AntidepressantsPsychiatric Annals, Vol. 50, No. 2Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder30 October 2019 | Expert Opinion on Pharmacotherapy, Vol. 21, No. 1Clinical overview of NMDA-R antagonists and clinical practiceEsketamine for treatment resistant depression: a trick of smoke and mirrors?16 December 2019 | Epidemiology and Psychiatric Sciences, Vol. 29Esketamine clinical trials: reply to Maju et al.29 April 2020 | Epidemiology and Psychiatric Sciences, Vol. 29Esketamine: new hope for the treatment of treatment-resistant depression? A narrative review23 July 2020 | Therapeutic Advances in Drug Safety, Vol. 11Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers11 May 2020 | Therapeutic Advances in Psychopharmacology, Vol. 10Esketamine and the Need for a New Type of Registry for Drugs With Abuse PotentialRupert McShane, M.D., F.R.C.Psych., David S. Baldwin, D.M., F.R.C.Psych., R. Hamish McAllister-Williams, Ph.D., F.R.C.Psych., James M. Stone, Ph.D., F.R.C.Psych., David Taylor, Ph.D., F.R.Pharm.S., Adam R. Winstock, M.D., M.R.C.Psych., Allan H. Young, Ph.D., F.R.C.Psych.1 November 2019 | American Journal of Psychiatry, Vol. 176, No. 11Comment on a Word to the Wise About Intranasal EsketamineWayne C. Drevets, M.D., Jaskaran B. Singh, M.D., David Hough, M.D., Ella J. Daly, M.D., Vanina Popova, M.D., Husseini Manji, M.D.1 October 2019 | American Journal of Psychiatry, Vol. 176, No. 10More Thoughts on Intranasal Esketamine: Response to Drevets et al.Alan F. Schatzberg, M.D.1 October 2019 | American Journal of Psychiatry, Vol. 176, No. 10Developing Novel Psychopharmacological Strategies and TherapeuticsNed H. Kalin, M.D.1 June 2019 | American Journal of Psychiatry, Vol. 176, No. 6Expert Review of Neurotherapeutics, Vol. 19, No. 10Annals of Internal Medicine, Vol. 171, No. 6 Volume 176Issue 6 June 01, 2019Pages 422-424 Metrics Featured in our Alexa Flash Briefing, Psychiatric News Brief. KeywordsEsketamineKetamineDepressionPDF download History Accepted 24 April 2019 Published online 21 May 2019 Published in print 1 June 2019
Referência(s)